07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Biolipox, Boehringer Ingelheim deal

Orexo AB (SSE:ORX; OTCQX:ORXOY, Uppsala, Sweden) said Boehringer returned all rights to OX-MPI , a preclinical program of prostaglandin E2 (PGE-2) inhibitors in development to treat chronic inflammatory pain conditions. Boehringer had rights to the...
07:00 , Jun 7, 2010 |  BioCentury  |  Strategy

J&J's Pulmonary Push

In a pair of deals last week, Johnson & Johnson doubled the number of compounds in its disclosed pipeline for respiratory diseases from four to eight, and it sounds like the pharma is still shopping....
07:00 , Sep 15, 2008 |  BC Week In Review  |  Company News

Orexo, Boehringer Ingelheim deal

The companies extended by one year the research phase of a 2005 partnership to develop Orexo's prostaglandin E synthase inhibitors to treat inflammation, pain and rheumatoid arthritis (RA). The compounds are in preclinical testing. Orexo,...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Company News

Inflazyme inflammation, neurology news

The company exited the pharmaceutical business. It had sold its remaining compounds to Biolipox AB last year. Biolipox was acquired by Orexo AB (SSE:ORX, Uppsala, Sweden) (see BioCentury, Oct. 1, 2007, & Dec. 3, 2007)....
07:00 , Mar 24, 2008 |  BC Week In Review  |  Clinical News

OX-NLA: Phase II data

Data from a double-blind, active- and placebo-controlled, Swedish Phase II trial of 25 subjects showed that cetirizine+liposomes in NLA nasal spray had local irritating characteristics that were comparable to placebo and less pronounced than those...
08:00 , Feb 14, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Asthma; rhinitis; chronic obstructive pulmonary disease (COPD) 15-lipoxygenase-1 pathway In vitro studies suggest that antagonizing the 15-lipoxygenase-1 pathway may be...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

Biolipox, Inflazyme, Orexo deal

Biolipox completed its previously announced acquisition of IZP's leukocyte selective anti-inflammatory drugs (LSAID) and phosphodiesterase-4 (PDE-4) inhibitor programs and its Prodaptin tethering technology (see BioCentury, Oct. 1). ORX completed its previously announced acquisition of Biolipox...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Company News

Biolipox, Orexo deal

NLA cetirizine is in Phase II testing to treat allergic and non-allergic rhinitis. BLX-CLI is a preclinical program for asthma and chronic obstructive pulmonary disease (COPD), and BLX-Eoxin consists of a portfolio of eoxin inhibitors...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

Biolipox, Orexo deal

ORX will acquire Biolipox for 8.6 million shares valued at SEK776.8 million ($120.9 million) based on ORX's close of SEK90.75 on Oct. 12, the last trading day before the deal was announced. Biolipox shareholders would...
07:00 , Oct 22, 2007 |  BioCentury  |  Finance

Ebb & Flow

Nektar (NKTR) was as surprised as anyone when Pfizer (PFE) announced last week that it would end further investment in Exubera inhaled insulin and return full worldwide rights to NKTR. The biotech, which developed and...